When delving into the science and logic behind Molecular Imprints Therapeutics (MIT), it becomes clear that the debate surrounding the use of single or multiple drugs in treatment is moot. MIT redefines the active principles of potentized drugs as diverse types of molecular imprints containing rendering the controversy irrelevant.
In MIT, the term ‘similimum’ refers to a drug substance capable of providing the specific molecular imprints necessary to correct the molecular errors causing a disease in a patient. The method of selecting the drug is secondary to its efficacy in curing the patient. Therefore, the similimum is effective if it can rectify the patient’s condition in its potentized form.
Patients often present with multiple molecular errors, each expressed through various symptoms. Consequently, they require multiple molecular imprints for treatment. If a single medicinal substance in its potentized form can provide all the needed imprints, it is sufficient. However, if no single substance can provide all the necessary imprints, multiple drug substances must be included in the prescription.
The primary concern is to ensure that the prescription delivers all the required molecular imprints to deactivate the pathogenic molecules indicated by the patient’s diverse symptoms. Thus, the focus shifts from the number of drugs to the molecular imprints they contain.
The MIT perspective challenges traditional views of classical homeopathy on single and compound drugs. A drug is considered single if it contains only one type of molecular imprint. If it contains multiple types of imprints, it is a compound drug, even if it originates from a single source material or is stored in one container.
When a complex drug substance is ingested in its crude form, it breaks down into individual chemical molecules, which then interact with various biological targets based on their molecular affinities. These interactions cause errors in biochemical pathways, leading to the symptoms observed.
Thus, the symptoms attributed to a drug substance are a collective manifestation of different molecular errors caused by various chemical molecules. It is crucial to recognize that substances like nux vomica or pulsatilla consist of multiple chemical molecules, each acting independently, making them compound drugs rather than single drugs.
From a pharmaceutical chemistry standpoint, a drug is a biologically active unit within a therapeutic agent. The chemical structure and properties of the molecule determine its medicinal properties. A substance containing only one type of biologically active unit is a single drug, while those with multiple types are compound drugs. Most homeopathic drugs, especially those of biological origin, fall into the compound category due to their diverse active units.
Potentized drugs, even if derived from a seemingly single substance, contain diverse molecular imprints representing the individual constituent molecules. These imprints act independently when applied to an organism, making potentized drugs compound drugs.
Classical homeopaths often object to the mixing or combination of potentized drugs. However, MIT supports the use of combinations of molecular imprinted forms (potencies above Avogadro limit – 12c and onwards) of multiple homeopathic drugs. These combinations are selected based on symptom analysis, miasmatic study, and biochemical evaluation.
MIT advocates for disease-specific combinations of molecular imprinted forms as effective curative agents. These combinations, selected based on common symptoms can alleviate symptoms, but may not offer total cure without incorporating drugs selected on pathophysiological grounds as well.
MIT views diseases as collections of pathological derangements caused by various molecular inhibitions from different pathogenic agents. Therapeutics, therefore, involves removing these inhibitions using appropriate molecular imprints. This understanding aligns with the principle of ‘similia similibus curentur,’ where pathological molecular inhibitions and their symptoms can be addressed by applying molecular imprints of drug molecules that cause similar inhibitions and symptoms in a healthy organism.
The debate over single versus multiple drugs becomes irrelevant when viewed through the lens of MIT. The focus shifts to the molecular imprints and their ability to correct molecular errors, regardless of the number of drugs involved. This scientific approach challenges classical homeopathy’s views and emphasizes the importance of understanding molecular interactions in effective treatment.
REDEFINING HOMEOPATHY 
Leave a comment